128 related articles for article (PubMed ID: 26584450)
1. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
Bressler NM; Varma R; Mitchell P; Suñer IJ; Dolan C; Ward J; Ferreira A; Ehrlich JS; Turpcu A
JAMA Ophthalmol; 2016 Feb; 134(2):160-6. PubMed ID: 26584450
[TBL] [Abstract][Full Text] [Related]
2. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
[TBL] [Abstract][Full Text] [Related]
3. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
[TBL] [Abstract][Full Text] [Related]
4. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
5. Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema.
Mandava NK; Kuriyan AE; Ho AC; Hsu J; Regillo CD; Klufas MA
Curr Opin Ophthalmol; 2024 May; 35(3):197-204. PubMed ID: 38345051
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of masking study participants to intravitreal injections in a randomized clinical trial.
Glassman AR; Stockdale CR; Beck RW; Baker C; Bressler NM;
Arch Ophthalmol; 2012 Feb; 130(2):190-4. PubMed ID: 22332211
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies.
Miller K; Fortun JA
Asia Pac J Ophthalmol (Phila); 2018; 7(1):28-35. PubMed ID: 29473719
[TBL] [Abstract][Full Text] [Related]
8. Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema.
Lloyd AJ; Loftus J; Turner M; Lai G; Pleil A
Health Qual Life Outcomes; 2013 Jan; 11():10. PubMed ID: 23347793
[TBL] [Abstract][Full Text] [Related]
9. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel.
Bandello F; Cunha-Vaz J; Chong NV; Lang GE; Massin P; Mitchell P; Porta M; Prünte C; Schlingemann R; Schmidt-Erfurth U
Eye (Lond); 2012 Apr; 26(4):485-93. PubMed ID: 22241014
[TBL] [Abstract][Full Text] [Related]
10. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States.
Bressler NM; Varma R; Doan QV; Gleeson M; Danese M; Bower JK; Selvin E; Dolan C; Fine J; Colman S; Turpcu A
JAMA Ophthalmol; 2014 Feb; 132(2):168-73. PubMed ID: 24357541
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema.
Varma R; Bressler NM; Doan QV; Suñer IJ; Danese M; Dolan CM; Lee A; Ehrlich JS; Rajput Y
Clin Ophthalmol; 2020; 14():1249-1259. PubMed ID: 32440092
[TBL] [Abstract][Full Text] [Related]
12. THE IMPACT OF BILATERAL VISION STATUS ON VISION-RELATED QUALITY OF LIFE IN PEOPLE WITH DIABETES MELLITUS.
Lin Z; Li D; Lin W; Wen L; Wang Y; Lin Z
Retina; 2024 Jun; 44(6):1021-1025. PubMed ID: 38194676
[TBL] [Abstract][Full Text] [Related]
13. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ; Khanani AM; Kaiser PK; Chang MA; Kovach JL; Lally DR; Rachitskaya A; Sheth VS; Vajzovic L; Clark J; Tang J; Zhu L; Desai D; Chakravarthy U
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38719191
[TBL] [Abstract][Full Text] [Related]
14. Current Perspectives of Bioptic Driving in Low Vision.
Chun R; Cucuras M; Jay WM
Neuroophthalmology; 2016 Apr; 40(2):53-58. PubMed ID: 27928386
[TBL] [Abstract][Full Text] [Related]
15. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
16. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
17. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
Bressler SB; Glassman AR; Almukhtar T; Bressler NM; Ferris FL; Googe JM; Gupta SK; Jampol LM; Melia M; Wells JA;
Am J Ophthalmol; 2016 Apr; 164():57-68. PubMed ID: 26802783
[TBL] [Abstract][Full Text] [Related]
19. Incidence and clinical features of post-injection endophthalmitis according to diagnosis.
Rayess N; Rahimy E; Shah CP; Wolfe JD; Chen E; DeCroos FC; Storey P; Garg SJ; Hsu J
Br J Ophthalmol; 2016 Aug; 100(8):1058-61. PubMed ID: 26584579
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
